These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 29550094)
1. Structure-based drug design of 1,3,6-trisubstituted 1,4-diazepan-7-ones as selective human kallikrein 7 inhibitors. Murafuji H; Sakai H; Goto M; Oyama Y; Imajo S; Sugawara H; Tomoo T; Muto T Bioorg Med Chem Lett; 2018 May; 28(8):1371-1375. PubMed ID: 29550094 [TBL] [Abstract][Full Text] [Related]
2. Structure-based drug design to overcome species differences in kallikrein 7 inhibition of 1,3,6-trisubstituted 1,4-diazepan-7-ones. Murafuji H; Sugawara H; Goto M; Oyama Y; Sakai H; Imajo S; Tomoo T; Muto T Bioorg Med Chem; 2018 Jul; 26(12):3639-3653. PubMed ID: 29884582 [TBL] [Abstract][Full Text] [Related]
3. Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors. Murafuji H; Sakai H; Goto M; Imajo S; Sugawara H; Muto T Bioorg Med Chem Lett; 2017 Dec; 27(23):5272-5276. PubMed ID: 29102227 [TBL] [Abstract][Full Text] [Related]
4. Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7. Arama DP; Soualmia F; Lisowski V; Longevial JF; Bosc E; Maillard LT; Martinez J; Masurier N; El Amri C Eur J Med Chem; 2015 Mar; 93():202-13. PubMed ID: 25682203 [TBL] [Abstract][Full Text] [Related]
5. Discovery and structure-activity relationship of imidazolinylindole derivatives as kallikrein 7 inhibitors. Murafuji H; Muto T; Goto M; Imajo S; Sugawara H; Oyama Y; Minamitsuji Y; Miyazaki S; Murai K; Fujioka H Bioorg Med Chem Lett; 2019 Jan; 29(2):334-338. PubMed ID: 30522951 [TBL] [Abstract][Full Text] [Related]
6. 3D-quantitative structure-activity relationship and docking studies of coumarin derivatives as tissue kallikrein 7 inhibitors. Zheng X; He M; Tan X; Zheng J; Wang F; Liu S J Pharm Pharmacol; 2017 Sep; 69(9):1136-1144. PubMed ID: 28543088 [TBL] [Abstract][Full Text] [Related]
7. Discovery of novel series of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones as human chymase inhibitors using structure-based drug design. Tanaka T; Sugawara H; Maruoka H; Imajo S; Muto T Bioorg Med Chem; 2013 Jul; 21(14):4233-49. PubMed ID: 23719288 [TBL] [Abstract][Full Text] [Related]
8. 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7. de Souza AS; Pacheco BDC; Pinheiro S; Muri EMF; Dias LRS; Lima CHS; Garrett R; de Moraes MBM; de Souza BEG; Puzer L Bioorg Med Chem Lett; 2019 May; 29(9):1094-1098. PubMed ID: 30833107 [TBL] [Abstract][Full Text] [Related]
9. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum. de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464 [TBL] [Abstract][Full Text] [Related]
10. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors. Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222 [TBL] [Abstract][Full Text] [Related]
11. Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening. Liang G; Chen X; Aldous S; Pu SF; Mehdi S; Powers E; Xia T; Wang R Bioorg Med Chem Lett; 2012 Apr; 22(7):2450-5. PubMed ID: 22386244 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557 [TBL] [Abstract][Full Text] [Related]
14. Crystal structure of human epidermal kallikrein 7 (hK7) synthesized directly in its native state in E. coli: insights into the atomic basis of its inhibition by LEKTI domain 6 (LD6). Fernández IS; Ständker L; Mägert HJ; Forssmann WG; Giménez-Gallego G; Romero A J Mol Biol; 2008 Apr; 377(5):1488-97. PubMed ID: 18329042 [TBL] [Abstract][Full Text] [Related]
15. Crystal structures of the complex of a kallikrein inhibitor from Bauhinia bauhinioides with trypsin and modeling of kallikrein complexes. Li M; Srp J; Gustchina A; Dauter Z; Mares M; Wlodawer A Acta Crystallogr D Struct Biol; 2019 Jan; 75(Pt 1):56-69. PubMed ID: 30644845 [TBL] [Abstract][Full Text] [Related]
16. Isomannide derivatives as new class of inhibitors for human kallikrein 7. Freitas RF; Teixeira TS; Barros TG; Santos JA; Kondo MY; Juliano MA; Juliano L; Blaber M; Antunes OA; Abrahão O; Pinheiro S; Muri EM; Puzer L Bioorg Med Chem Lett; 2012 Oct; 22(19):6072-5. PubMed ID: 22959247 [TBL] [Abstract][Full Text] [Related]
17. Ahp-Cyclodepsipeptides as tunable inhibitors of human neutrophil elastase and kallikrein 7: Total synthesis of tutuilamide A, serine protease selectivity profile and comparison with lyngbyastatin 7. Chen QY; Luo D; Seabra GM; Luesch H Bioorg Med Chem; 2020 Dec; 28(23):115756. PubMed ID: 33002682 [TBL] [Abstract][Full Text] [Related]
18. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Katz BA; Liu B; Barnes M; Springman EB Protein Sci; 1998 Apr; 7(4):875-85. PubMed ID: 9568894 [TBL] [Abstract][Full Text] [Related]
19. Visualizing protein-ligand binding with chemical energy-wise decomposition (CHEWD): application to ligand binding in the kallikrein-8 S1 Site. Raza S; Ranaghan KE; van der Kamp MW; Woods CJ; Mulholland AJ; Azam SS J Comput Aided Mol Des; 2019 May; 33(5):461-475. PubMed ID: 30989572 [TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors. Kawakita Y; Seto M; Ohashi T; Tamura T; Yusa T; Miki H; Iwata H; Kamiguchi H; Tanaka T; Sogabe S; Ohta Y; Ishikawa T Bioorg Med Chem; 2013 Apr; 21(8):2250-2261. PubMed ID: 23490150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]